PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.96%
Growth of 4.96% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
4.19%
Cost growth of 4.19% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
8.17%
Growth of 8.17% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
3.06%
Margin change of 3.06% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-3.06%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
3.36%
Operating expenses growth 1.25-1.5x Medical - Pharmaceuticals median of 2.37%. Guy Spier would scrutinize spending.
4.06%
Total costs growth 1.25-1.5x Medical - Pharmaceuticals median of 2.73%. Guy Spier would scrutinize spending.
-4.17%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-3.42%
D&A reduction while Medical - Pharmaceuticals median is 1.59%. Seth Klarman would investigate efficiency.
24.45%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
18.56%
Margin change of 18.56% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
28.69%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
22.60%
Margin change of 22.60% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-7.54%
Other expenses reduction while Medical - Pharmaceuticals median is 10.85%. Seth Klarman would investigate advantages.
24.57%
Income change of 24.57% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
18.68%
Margin change of 18.68% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
1573.15%
Tax expense growth exceeding 1.5x Medical - Pharmaceuticals median of 9.57%. Jim Chanos would check for issues.
-17.71%
Net income decline while Medical - Pharmaceuticals median is -4.55%. Seth Klarman would investigate causes.
-21.60%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-17.71%
EPS decline while Medical - Pharmaceuticals median is -1.72%. Seth Klarman would investigate causes.
-17.71%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
0.00%
Share count reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.04%. Joel Greenblatt would investigate strategy.
0.00%
Diluted share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.01%. Joel Greenblatt would investigate strategy.